Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: A systematic review of clinical trials
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Purpose: Brain tumors, particularly glioblastoma multiforme (GBM), present significant prognostic challenges despite multimodal therapies, including surgical resection, chemotherapy, and radiotherapy. One major obstacle is the limited drug delivery across the blood–brain barrier (BBB). Focused ultrasound (FUS) combined with systemically administered microbubbles has emerged as a non-invasive, targeted, and reversible approach to transiently open the BBB, thus enhancing drug delivery. This review examines clinical trials employing BBB opening techniques to optimise pharmacotherapy for brain tumors, evaluates current challenges, and proposes directions for further research. Methods: A systematic literature search was conducted in PubMed and ClinicalTrials.gov up to November 2023, searching for “ultrasound” AND “brain tumor”. The search yielded 1446 results. After screening by title and abstract, followed by full-text screening (n = 48), 35 studies were included in the analysis. Results: Our analysis includes data from 11 published studies and 24 ongoing trials. The predominant focus of these studies is on glioma, including GMB and astrocytoma. One paper investigated brain metastasis from breast cancer. Evidence indicates that FUS facilitates BBB opening and enhances drug uptake following sonication. Exploration of FUS in the pediatric population is limited, with no published studies and only three ongoing trials dedicated to this demographic. Conclusion: FUS is a promising strategy to safely disrupt the BBB, enabling precise and non-invasive lesion targeting, and enhance drug delivery. However, pharmacokinetic studies are required to quantitatively assess improvements in drug uptake. Most studies are phase I clinical trials, and long-term follow-up investigating patient outcomes is essential to evaluate the clinical benefit of this treatment approach. Further studies involving diverse populations and pathologies will be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, FUS combined with MBs is a method that uses ultrasound waves directed at specific areas of the brain to cause oscillation of the MBs circulating in the blood, producing mechanical forces within blood vessels that temporarily and safely loosen the TJs of the BBB.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [81]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consequently, the BBB becomes more permeable, allowing therapeutic drugs to pass more easily from the bloodstream into the brain tissue”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 2×
“The BBB, formed by microvascular endothelial cells that regulate molecule and ion transfer from the blood into the brain parenchyma, enables homeostasis and normal neuronal functioning [3].”
BackgroundA blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853 · cited 1×
“Consequently, there is growing interest in research focused on safe and reversible BBB opening (BBBO), which holds promise for enhancing the delivery and efficacy of therapeutic agents [4].”
BackgroundWen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · cited 1×
“Brain tumors continue to exhibit a poor prognosis, with less than 20% of patients surviving beyond 5 years post-diagnosis [1].”
BackgroundClinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757 · cited 3×
“The drugs used following FUS-guided BBBO included paclitaxel [25] and carboplatin [26– 28] for recurrent GBM, and temozolomide (TMZ) for GBM [29, 30] and M e ng e t a l .”
MethodMainprize, T., Lipsman, N., Huang, Y., Meng, Y., Bethune, A., Ironside, S., Heyn, C., Alkins, R., Trudeau, M., Sahgal, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36340-0 · Cited by 618 · cited 7×
“The contrast extravasation occurred in a grid pattern with ExAblate which resolved within 24 h [24, 31], and in a cylindrical pattern with SonoCloud-9, which resolved within an hour [25].”
BackgroundInfluentialBatchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614 · cited 1×
“In a placebo-controlled phase III trial, cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, did not improve progression-free survival in patients with recurrent GBM [54].”
BackgroundMcDannold, N., Arvanitis, C. D., Vykhodtseva, N., & Livingstone, M. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0128 · Cited by 588
Sheikov, N., McDannold, N., Sharma, S., & Hynynen, K. (2008) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2007.12.015 · Cited by 493 · cited 1×
“MRgFUS disrupts the BBB through multiple mechanisms, such as direct disruption of tight junctions and induced transcytosis [44].”
BackgroundAbrahao, A., Meng, Y., Llinas, M., Huang, Y., Hamani, C., Mainprize, T., Aubert, I., Heyn, C., Black, S. E., Hynynen, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12426-9 · Cited by 476 · cited 1×
“Its feasibility has also been explored in amyotrophic lateral sclerosis (ALS) [53].”
BackgroundDynamics of CNS Barriers: Evolution, Differentiation, and Modulation
Abbott, N. J. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1374-y · Cited by 469 · cited 1×
“These cells interact with astrocytes and pericytes to uphold the barrier’s integrity [5].”
BackgroundO’Reilly, M. A., & Hynynen, K. (2012) · Radiology · doi:10.1148/radiol.11111417 · Cited by 401 · cited 1×
“Magnetic resonance-guided focused ultrasound (MRgFUS) offers a promising approach, as multiple studies have demonstrated its ability to temporarily disrupt the BBB without damaging surrounding tissues [43].”
BackgroundLiu, H.-L., Hua, M.-Y., Chen, P.-Y., Chu, P.-C., Pan, C.-H., Yang, H.-W., Huang, C.-Y., Wang, J.-J., Yen, T.-C., & Wei, K.-C. (2010) · Radiology · doi:10.1148/radiol.10090699 · Cited by 393
Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 362 · cited 2×
“Side effects generally diminish with steroid treatment [29], and resolved within 1 to 48 h in one study [27].”
BackgroundAryal, M., Vykhodtseva, N., Zhang, Y.-Z., Park, J., & McDannold, N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.007 · Cited by 261 · cited 2×
“Each of these drugs has distinct molecular properties, such as molecular weight or lipophilicity, enabling them to readily pass through the BBB with the assistance of FUS-mediated BBBO, as shown in pre-clinical trials [35–37].”
BackgroundSonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., Gomez, C., Bebawy, J. F., Liu, B. P., Bouchoux, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00112-2 · Cited by 260
Wei, K.-C., Chu, P.-C., Wang, H.-Y. J., Huang, C.-Y., Chen, P.-Y., Tsai, H.-C., Lu, Y.-J., Lee, P.-Y., Tseng, I.-C., Feng, L.-Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058995 · Cited by 238 · cited 1×
“Each of these drugs has distinct molecular properties, such as molecular weight or lipophilicity, enabling them to readily pass through the BBB with the assistance of FUS-mediated BBBO, as shown in pre-clinical trials [35–37].”
BackgroundMR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases
Meng, Y., Reilly, R. M., Pezo, R. C., Trudeau, M., Sahgal, A., Singnurkar, A., Perry, J., Myrehaug, S., Pople, C. B., Davidson, B., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj4011 · Cited by 232 · cited 7×
“The contrast extravasation occurred in a grid pattern with ExAblate which resolved within 24 h [24, 31], and in a cylindrical pattern with SonoCloud-9, which resolved within an hour [25].”
BackgroundMethodInfluentialSulahian, A., Boutboul, F., Ribaud, P., Leblanc, T., Lacroix, C., & Derouin, F. (2001) · Cancer · doi:10.1002/1097-0142(20010115)91:2<311::aid-cncr1003>3.0.co;2-3 · Cited by 226
Downs, M. E., Buch, A., Sierra, C., Karakatsani, M. E., Chen, S., Konofagou, E. E., & Ferrera, V. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125911 · Cited by 220 · cited 1×
“Other studies have shown that BBBO does not affect cognitive performance of NHPs post-treatment, further indicating the safety of FUS [17, 23].”
The use of microbubbles to target drug delivery
Tsutsui, J. M., Xie, F., & Porter, R. T. (2004) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-2-23 · Cited by 215 · cited 1×
“Drugs can be administered either concurrently with microbubbles or bound to their shell via ligands for localized release [13].”
BackgroundChen, K.-T., Chai, W.-Y., Lin, Y.-J., Lin, C.-J., Chen, P.-Y., Tsai, H.-C., Huang, C.-Y., Kuo, J. S., Liu, H.-L., & Wei, K.-C. (2021) · Science Advances · doi:10.1126/sciadv.abd0772 · Cited by 202 · cited 2×
“[ 33 , 34 ] C a r p e n ti e r e t a l .”
BackgroundVan Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198 · cited 1×
“Furthermore, promising in vitro chemotherapeutic agents should undergo investigation with FUS [57].”
BackgroundPassive cavitation imaging with ultrasound arrays
Salgaonkar, V. A., Datta, S., Holland, C. K., & Mast, T. D. (2009) · The Journal of the Acoustical Society of America · doi:10.1121/1.3238260 · Cited by 184 · cited 1×
“However, these techniques have their own limitations, such as variable sensitivity, limited resolution, and computational speeds [45–47].”
BackgroundZhang, D. Y., Dmello, C., Chen, L., Arrieta, V. A., Gonzalez-Buendia, E., Kane, J. R., Magnusson, L. P., Baran, A., James, C. D., Horbinski, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2182 · Cited by 176 · cited 1×
“However, despite its potency, paclitaxel does not cross the BBB [41], and has not shown efficacy for glioma in clinical trials [42].”
BackgroundAnastasiadis, P., Gandhi, D., Guo, Y., Ahmed, A.-K., Bentzen, S. M., Arvanitis, C., & Woodworth, G. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103280118 · Cited by 175
Ortiz, R., Perazzoli, G., Cabeza, L., Jiménez-Luna, C., Luque, R., Prados, J., & Melguizo, C. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200626204005 · Cited by 171 · cited 1×
“Despite its efficacy, its cerebrospinal fluid concentration is only about 20% of plasma concentration [38], and the median survival in GBM patients following traditional treatment with surgery, radiation, and TMZ is only 14.6 months [38].”
BackgroundInfluentialWu, S.-K., Chu, P.-C., Chai, W.-Y., Kang, S.-T., Tsai, C.-H., Fan, C.-H., Yeh, C.-K., & Liu, H.-L. (2017) · Scientific Reports · doi:10.1038/srep46689 · Cited by 154 · cited 1×
“A study in rats suggest similar BBBO effects under equivalent concentrations [49].”
BackgroundPark, S. H., Kim, M. J., Jung, H. H., Chang, W. S., Choi, H. S., Rachmilevitch, I., Zadicario, E., & Chang, J. W. (2021) · Journal of Neurosurgery · doi:10.3171/2019.10.jns192206 · Cited by 139 · cited 5×
“However, MRgFUS procedures require fixation of stere-otaxic frame with regular frame adjustments, which may cause discomfort and emotional stress [30].”
BackgroundMethodInfluentialImproving CNS Delivery to Brain Metastases by Blood–Tumor Barrier Disruption
Sprowls, S. A., Arsiwala, T. A., Bumgarner, J. R., Shah, N., Lateef, S. S., Kielkowski, B. N., & Lockman, P. R. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.06.003 · Cited by 122 · cited 2×
“The challenge of drug delivery is compounded by localized vascular changes in tumors, which can increase interstitial fluid pressure (IFP), complicating the dynamics of drug delivery [6].”
BackgroundCho, H., Lee, H.-Y., Han, M., Choi, J.-R., Ahn, S., Lee, T., Chang, Y., & Park, J. (2016) · Scientific Reports · doi:10.1038/srep31201 · Cited by 120 · cited 1×
“Nonetheless, P-gp is shown to be down-regulated after treatment with FUS and microbubbles [40], and TMZ concentration has been shown to increase by 7.7-fold when BBBO is performed concomitantly [29].”
BackgroundInfluentialRezai, A. R., Ranjan, M., Haut, M. W., Carpenter, J., D’Haese, P.-F., Mehta, R. I., Najib, U., Wang, P., Claassen, D. O., Chazen, J. L., et al. (2023) · Journal of Neurosurgery · doi:10.3171/2022.9.jns221565 · Cited by 111
Convection-Enhanced Delivery: Connection to and Impact of Interstitial Fluid Flow
Stine, C. A., & Munson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00966 · Cited by 107 · cited 1×
“However, backflow presents as a significant challenge, where the infusion penetrates through the catheter tract rather than reaching the targeted area [9].”
BackgroundBlood-brain barrier disruption using mannitol: time course and electron microscopy studies
Cosolo, W. C., Martinello, P., Louis, W. J., & Christophidis, N. (1989) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1989.256.2.r443 · Cited by 101 · cited 1×
“One involves administering hyperosmotic agents like mannitol via intra-arterial infusion [7].”
BackgroundJones, R. M., O’Reilly, M. A., & Hynynen, K. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/14/4981 · Cited by 100
Park, S. H., Kim, M. J., Jung, H. H., Chang, W. S., Choi, H. S., Rachmilevitch, I., Zadicario, E., & Chang, J. W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01663 · Cited by 98 · cited 4×
“Side effects generally diminish with steroid treatment [29], and resolved within 1 to 48 h in one study [27].”
BackgroundMethodInfluentialPassive Acoustic Mapping with the Angular Spectrum Method
Arvanitis, C., Crake, C., McDannold, N. J., & Clement, G. T. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2643565 · Cited by 97 · cited 1×
“However, these techniques have their own limitations, such as variable sensitivity, limited resolution, and computational speeds [45–47].”
BackgroundSafety Validation of Repeated Blood–Brain Barrier Disruption Using Focused Ultrasound
Kobus, T., Vykhodtseva, N., Pilatou, M., Zhang, Y., & McDannold, N. (2016) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.10.009 · Cited by 94 · cited 1×
“Pre-clinical studies on mice, rats, rabbits, canines, and non-human primates (NHPs) have demonstrated safe, effective, and reversible BBBO with ultrasound and microbubbles, leading to human clinical trials to assess efficacy and safety in clinical settings [14–19].”
BackgroundEnglander, Z. K., Wei, H.-J., Pouliopoulos, A. N., Bendau, E. V., Upadhyayula, P. S., Jan, C., Spinazzi, E. F., Yoh, N. T., Tazhibi, M., McQuillan, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85180-y · Cited by 93 · cited 1×
“For example, evidence has shown that FUS-mediated BBBO is safe in mice with diffuse intrinsic pontine gliomas (DIPG) [20–22].”
BackgroundSelf-citationPouliopoulos, A. N., Kwon, N., Jensen, G., Meaney, A., Niimi, Y., Burgess, M. T., Ji, R., McLuckie, A. J., Munoz, F. A., Kamimura, H. A. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94188-3 · Cited by 85 · cited 1×
“Other studies have shown that BBBO does not affect cognitive performance of NHPs post-treatment, further indicating the safety of FUS [17, 23].”
Self-citationPhase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84 · cited 1×
“The same applies to other drugs like tivozanib and sunitinib [55, 56].”
BackgroundChen, K.-T., Lin, Y.-J., Chai, W.-Y., Lin, C.-J., Chen, P.-Y., Huang, C.-Y., Kuo, J. S., Liu, H.-L., & Wei, K.-C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-344 · Cited by 84 · cited 1×
“[ 33 , 34 ] C a r p e n ti e r e t a l .”
Hutterer, M., Nowosielski, M., Haybaeck, J., Embacher-Aichhorn, S., Stockhammer, F., Gotwald, T., Holzner, B., Capper, D., Preusser, M., Marosi, C., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not161 · Cited by 80 · cited 1×
“The same applies to other drugs like tivozanib and sunitinib [55, 56].”
BackgroundSite‐specific opening of the blood‐brain barrier
Madsen, S. J., & Hirschberg, H. (2010) · Journal of Biophotonics · doi:10.1002/jbio.200900095 · Cited by 73 · cited 1×
“Other techniques, such as implanting drug-releasing polymers, and conjugation of pharmacotherapies to proteins, also face drawbacks (e.g. reduced delivery and rapid clearance from circulation) [10].”
BackgroundAdkins, C. E., Mittapalli, R. K., Manda, V. K., Nounou, M. I., Mohammad, A. S., Terrell, T. B., Bohn, K. A., Yasemin, C., Grothe, T. R., Lockman, J. A., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00136 · Cited by 69 · cited 1×
“This limitation may stem from efflux by the P-glycoprotein 1 (P-gp), a common multidrug resistant protein abundant in BBB within cancerous tissues, as shown in rats [39].”
BackgroundIshida, J., Alli, S. B., Bondoc, A., Golbourn, B. J., Sabha, N., Mikloska, K., Krumholtz, S. L., Srikanthan, D., Fujita, N., Luck, A. J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.010 · Cited by 69 · cited 1×
“For example, evidence has shown that FUS-mediated BBBO is safe in mice with diffuse intrinsic pontine gliomas (DIPG) [20–22].”
BackgroundChai, W., Chu, P., Tsai, M.-Y., Lin, Y., Wang, J., Wei, K., Wai, Y., & Liu, H.-L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.023 · Cited by 68 · cited 1×
“Appropriate ultrasound parameters are crucial to avoid risks such as erythrocyte extravasations in cerebral microvasculature, limiting the incremental ultrasound level below 0.8 mechanical index (MI) [50].”
BackgroundInfluentialO'Reilly, M. A., Jones, R. M., Barrett, E., Schwab, A., Head, E., & Hynynen, K. (2017) · Theranostics · doi:10.7150/thno.20621 · Cited by 67 · cited 1×
“Pre-clinical studies on mice, rats, rabbits, canines, and non-human primates (NHPs) have demonstrated safe, effective, and reversible BBBO with ultrasound and microbubbles, leading to human clinical trials to assess efficacy and safety in clinical settings [14–19].”
BackgroundLinville, R. M., DeStefano, J. G., Sklar, M. B., Chu, C., Walczak, P., & Searson, P. C. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19867980 · Cited by 67 · cited 1×
“However, the dilutional effects of collateral arterial system in the Circle of Willis complicates its reproducibility [8].”
BackgroundMcDannold, N., Zhang, Y., & Vykhodtseva, N. (2011) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2011.04.019 · Cited by 65 · cited 1×
“FUS-mediated BBBO is non-invasive and can be precisely controlled, making it a promising approach for treating brain tumors and other neurological disorders while minimizing systemic side effects [11].”
BackgroundMultiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy
Kumari, S., Gupta, R. V., Ambasta, R. K., & Kumar, P. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188913 · Cited by 61 · cited 1×
“Despite various therapeutic modalities, including surgery, chemotherapy and radiotherapy, substantial improvements in patient survival have not been realised [2].”
BackgroundMartinez, P. J., Nault, G., Steiner, J., Wempe, M. F., Pierce, A. M., Brunt, B., Slade, M., Song, J. J., Mongin, A., Song, K.-H., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad111 · Cited by 57
Bae, S., Liu, K., Pouliopoulos, A. N., Ji, R., & Konofagou, E. E. (2023) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2023.3266952 · Cited by 52 · cited 1×
“Imaging microbubble acoustic emissions in 2D and 3D can identify the spatial location of microbubble activity, which can be correlated with the degree of gadolinium penetration into the brain, a typical surrogate for BBBO confirmation, or directly with the degree of drug delivery [48].”
BackgroundSelf-citationAsquier, N., Bouchoux, G., Canney, M., Martin, C., Law-Ye, B., Leclercq, D., Chapelon, J.-Y., Lafon, C., Idbaih, A., & Carpentier, A. (2020) · Journal of Neurosurgery · doi:10.3171/2018.9.jns182001 · Cited by 50 · cited 3×
“The drugs used following FUS-guided BBBO included paclitaxel [25] and carboplatin [26– 28] for recurrent GBM, and temozolomide (TMZ) for GBM [29, 30] and M e ng e t a l .”
BackgroundMethodOlumolade, O. O., Wang, S., Samiotaki, G., & Konofagou, E. E. (2016) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2016.05.004 · Cited by 48
Blackmore, D. G., Turpin, F., Mohamed, A. Z., Zong, F., Pandit, R., Pelekanos, M., Nasrallah, F., Sah, P., Bartlett, P. F., & Götz, J. (2018) · Theranostics · doi:10.7150/thno.27941 · Cited by 42
Kong, C., & Chang, W. S. (2023) · Neurology International · doi:10.3390/neurolint15010018 · Cited by 37 · cited 1×
“Additionally, targeted immunotherapies, such as monoclonal antibodies or CAR-T cell therapies, could benefit from localized and reversible FUS-mediated BBBO in brain tumor patients [58].”
BackgroundFocused Ultrasound Treatment, Present and Future
Abe, K., & Taira, T. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0024 · Cited by 34 · cited 2×
“Currently, the use of ultrasound with microbubbles is the only non-invasive, targeted, and reversible method for transient BBBO to enhance drug delivery [12].”
BackgroundMethodSyed, H. R., Kilburn, L. B., Fonseca, A., Nazarian, J., Oluigbo, C. O., Myseros, J. S., Packer, R. J., & Keating, R. F. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04269-8 · Cited by 30
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Touat, M., Khasraw, M., Rahman, R. M., Platten, M., Lim, M. K., Winkler, F., Horbinski, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf177 · Cited by 136
Nanotherapy of Glioblastoma—Where Hope Grows
Grzegorzewski, J., Michalak, M., Wołoszczuk, M., Bulicz, M., & Majchrzak‐Celińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051814 · Cited by 54
Kashkooli, F. M., Bhandari, A., Gu, B., Kolios, M. C., Kohandel, M., & Zhan, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114138 · Cited by 35
Costea, D., Dobrin, N., Tătaru, C.-I., Toader, C., Șerban, M., Covache-Busuioc, R.-A., Munteanu, O., & Diaconescu, B. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110546 · Cited by 31
Acoustic emissions dose and spatial control of blood-brain barrier opening with focused ultrasound
Woodworth, G. F., Anastasiadis, P., Ozair, A., Chen, C., Gandhi, D., Meng, Y., Abrahão, A., Carpenter, J., Cifarelli, C. P., Eisenberg, H. M., et al. (2025) · Device · doi:10.1016/j.device.2025.100894 · Cited by 21
Metadata
- Authors
- Zhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N.
- Affiliations
- King's College London (GB)
- Corresponding author
- Pouliopoulos, Antonios N.
- Venue
- Journal of Neuro-Oncology
- Published
- 2024-08-29
- Volume
- 170
- Issue
- 2
- Pages
- 235-252
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- PMC
- PMC11538134
- OpenAlex
- W4402005298
- Semantic Scholar
- d3b4161918e04b949992213e6e571a0617e473d7
- Cited by
- 75
- References
- 58
- Citations by year
- 2026: 43 · 2025: 32
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neuro-Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Children’s Cancer and Leukaemia Group (CCLG) / Little Princess Trust (CCLGA 2022 25)
- Action Medical Research / LifeArc (GN3017)
- Focused Ultrasound Foundation (FUS1050R1)
- Abbie’s Army / Children’s Brain Tumour Drug Delivery Consortium (KCL/G12/22)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- focused ultrasound, blood-brain barrier opening, brain tumors, glioblastoma, glioma, astrocytoma, brain metastases, breast cancer, microbubbles, drug delivery, clinical trials, pediatric brain tumors
- MeSH terms
- Antineoplastic Agents, Blood-Brain Barrier, Brain Neoplasms, Clinical Trials as Topic, Humans, Permeability, Ultrasonic Therapy, Drug Delivery Systems, Microbubbles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.